|
BioCryst Pharmaceuticals, Inc. (BCRX) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
BioCryst Pharmaceuticals, Inc. (BCRX) Bundle
Gain insight into your BioCryst Pharmaceuticals, Inc. (BCRX) valuation analysis with our cutting-edge DCF Calculator! Preloaded with real (BCRX) data, this Excel template empowers you to adjust forecasts and assumptions to accurately determine BioCryst's intrinsic value.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.8 | 17.8 | 157.2 | 270.8 | 331.4 | 440.1 | 584.4 | 776.0 | 1,030.4 | 1,368.3 |
| Revenue Growth, % | 0 | -63.53 | 782.38 | 72.31 | 22.37 | 32.79 | 32.79 | 32.79 | 32.79 | 32.79 |
| EBITDA | -96.3 | -167.6 | -121.7 | -143.9 | -116.3 | -321.9 | -427.4 | -567.5 | -753.6 | -1,000.7 |
| EBITDA, % | -197.16 | -940.74 | -77.46 | -53.12 | -35.1 | -73.14 | -73.14 | -73.14 | -73.14 | -73.14 |
| Depreciation | .7 | .7 | .8 | 1.4 | 1.7 | 6.3 | 8.4 | 11.2 | 14.9 | 19.7 |
| Depreciation, % | 1.48 | 4.2 | 0.49437 | 0.5306 | 0.49938 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 |
| EBIT | -97.0 | -168.3 | -122.5 | -145.3 | -118.0 | -323.2 | -429.2 | -569.9 | -756.8 | -1,004.9 |
| EBIT, % | -198.64 | -944.94 | -77.95 | -53.65 | -35.6 | -73.44 | -73.44 | -73.44 | -73.44 | -73.44 |
| Total Cash | 136.2 | 300.4 | 514.4 | 442.4 | 389.0 | 440.1 | 584.4 | 776.0 | 1,030.4 | 1,368.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 22.1 | 8.6 | 29.4 | 50.6 | 57.0 | 130.7 | 173.5 | 230.4 | 306.0 | 406.3 |
| Account Receivables, % | 45.35 | 48.54 | 18.71 | 18.68 | 17.18 | 29.69 | 29.69 | 29.69 | 29.69 | 29.69 |
| Inventories | 1.6 | 7.0 | 15.8 | 27.5 | 28.7 | 63.0 | 83.6 | 111.1 | 147.5 | 195.8 |
| Inventories, % | 3.18 | 39.52 | 10.05 | 10.17 | 8.65 | 14.31 | 14.31 | 14.31 | 14.31 | 14.31 |
| Accounts Payable | 14.0 | 18.7 | 27.8 | 14.4 | 20.9 | 139.0 | 184.6 | 245.1 | 325.5 | 432.2 |
| Accounts Payable, % | 28.64 | 105.06 | 17.69 | 5.3 | 6.3 | 31.59 | 31.59 | 31.59 | 31.59 | 31.59 |
| Capital Expenditure | -.3 | -.5 | -2.4 | -1.4 | -2.2 | -5.5 | -7.3 | -9.7 | -12.9 | -17.1 |
| Capital Expenditure, % | -0.70237 | -2.89 | -1.52 | -0.49884 | -0.65417 | -1.25 | -1.25 | -1.25 | -1.25 | -1.25 |
| Tax Rate, % | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 |
| EBITAT | -107.0 | -181.0 | -124.0 | -146.9 | -118.2 | -323.2 | -429.2 | -569.9 | -756.8 | -1,004.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -116.3 | -168.0 | -146.1 | -193.2 | -119.6 | -312.3 | -446.0 | -592.2 | -786.4 | -1,044.3 |
| WACC, % | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,076.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,065 | |||||||||
| Terminal Value | -9,564 | |||||||||
| Present Terminal Value | -5,160 | |||||||||
| Enterprise Value | -7,236 | |||||||||
| Net Debt | 715 | |||||||||
| Equity Value | -7,951 | |||||||||
| Diluted Shares Outstanding, MM | 192 | |||||||||
| Equity Value Per Share | -41.37 |
What You Will Get
- Real BCRX Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess BioCryst's future performance.
- User-Friendly Design: Designed for industry professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life BCRX Financials: Pre-filled historical and projected data for BioCryst Pharmaceuticals, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate BioCryst’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize BioCryst’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for BioCryst Pharmaceuticals, Inc. (BCRX).
- Step 2: Review the pre-entered data for BioCryst (historical and projected).
- Step 3: Adjust key assumptions (highlighted in yellow) based on your analysis.
- Step 4: Observe the automatic recalculations for BioCryst's intrinsic value.
- Step 5: Utilize the outputs for your investment decisions or reporting needs.
Why Choose BioCryst Pharmaceuticals, Inc. (BCRX)?
- Innovative Solutions: Pioneering treatments that address unmet medical needs in rare diseases.
- Proven Expertise: A team of seasoned professionals dedicated to advancing pharmaceutical science.
- Commitment to Quality: Rigorous testing and development processes ensure high standards in our products.
- Patient-Centric Approach: Focused on improving patient outcomes and enhancing quality of life.
- Strong Pipeline: A robust portfolio of drug candidates that promise future growth and value.
Who Should Use BioCryst Pharmaceuticals, Inc. (BCRX)?
- Pharmaceutical Students: Understand drug development processes and apply them to real-world case studies.
- Researchers: Utilize innovative models in your studies related to rare diseases and treatments.
- Investors: Evaluate your investment strategies and analyze the market potential of BioCryst's pipeline.
- Healthcare Analysts: Enhance your analysis with a tailored approach to assessing biotech companies.
- Medical Professionals: Learn how pharmaceutical companies like BioCryst are shaping the future of treatments.
What the Template Contains
- Pre-Filled Data: Includes BioCryst Pharmaceuticals’ historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze BioCryst Pharmaceuticals’ profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.